Overview

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study is a preliminary proof of efficacy study of AIN457 in patients with bronchial asthma that is poorly controlled with the current standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal